• Explore /
  • Poster
  • / Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).

Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).

Abstract Poster

Authors

null

Patrick Y. Wen

Dana-Farber Cancer Institute, Boston, MA

Patrick Y. Wen , W. K. Alfred Yung , Ingo K. Mellinghoff , Kathleen Lamborn , Shakti Ramkissoon , Timothy Francis Cloughesy , Mikael Rinne , Antonio Marcilio Padula Omuro , Lisa Marie DeAngelis , Mark R. Gilbert , Andrew S. Chi , Tracy Batchelor , Howard Colman , Susan Marina Chang , Cristian Massacesi , Emmanuelle DiTomaso , Michael Prados , David A. Reardon , Keith L. Ligon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT01339052

Citation

J Clin Oncol 31, 2013 (suppl; abstr 2015)

DOI

10.1200/jco.2013.31.15_suppl.2015

Abstract #

2015

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Patrick Y. Wen

First Author: Patrick Y. Wen

First Author: Gayathri Nagaraj

First Author: Pierre-Etienne Heudel